3 results
To assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer*s disease-causing mutation by determining if treatment with the study drug slows the rate of progression…
Primary Objective:The primary objective of this study is to determine whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive…
Cross validation of the hybrid tracer ICG 99 Tc Nanoscan with respect to 99m Tc Nanoscan for the determination. In particular the intraoperative fluorescence detection and scintillation detection will be validated for ICG 99 Tc Nanoscan. In addition…